EUCTR2010-020493-42-BG进行中（未招募）1 期
A Double-blind, Randomized, Placebo-controlled, Multicentre, Relapse-prevention Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •De novo patients
- •The patient has a primary diagnosis of MDD according to DSM-5™ although co-morbid anxiety disorders will be permitted (except Post Traumatic Stress Disorder (PTSD) and Obsessive Compulsive Disorder
- •The patient has a CDRS-R total score =45 at the Screening and Baseline Visits.
- •The patient has a Clinical Global Impression – Severity of Illness (CGI-S) =4 at the Screening and Baseline Visit
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 150
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •De novo patients and roll over patients from studies 12709A and 12712A
- •The patient receives ongoing current psychotherapy that is planned to be intensified. Interpersonal psychotherapy (IPT) or cognitive behavioural therapy (CBT) are not allowed.
- •The patient presents with, or has a history of, an Axis I (DSM-5TM) diagnosis of Bipolar Disorder, PTSD, OCD, Autism, Pervasive Developmental Disorder (PDD), or Schizophrenia or Schizoaffective Disorder.
- •The patient has a diagnosis of attention-deficit/hyperactivity disorder (ADHD) and is not maintained on a stable dose of a methylphenidate or amphetamine for a minimum of 4 weeks prior to the study treatment.
- •The patient has attempted suicide or is at significant risk of suicide.
研究者
相似试验
进行中（未招募）
不适用
A research study to find out if people with Primary Generalized Tonic-Clonic Seizures, by taking perampanel in addition to their normal epilepsy medicine(s), have fewer seizures and feel better. Either perampanel (real medicine) or placebo (pretend medicine that looks the same as the real medicine) will be given in addition to ordinary epilepsy medicines. Who gets which is decided randomly. There is an option to continue into the Follow-on (Extension) Phase of the study.EUCTR2011-000265-12-NLEisai Limited164
进行中（未招募）
1 期
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeDyslipidemiaMedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2018-004565-14-PTAmgen Inc.13,000
进行中（未招募）
不适用
Study to assess the tolerability and efficacy of AMG 145 in patients with heterozygous familial hypercholesterolemiaHeterozygous familial hypercholesterolaemiaMedDRA version: 14.0Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001528-39-SEAmgen Inc150
进行中（未招募）
不适用
A research study to find out if people with Primary Generalized Tonic-Clonic Seizures, by taking perampanel in addition to their normal epilepsy medicine(s), have fewer seizures and feel better. Either perampanel (real medicine) or placebo (pretend medicine that looks the same as the real medicine) will be given in addition to ordinary epilepsy medicines. Who gets which is decided randomly. There is an option to continue into the Follow-on (Extension) Phase of the study.Primary Generalized Tonic-Clonic SeizuresMedDRA version: 14.1Level: HLTClassification code 10018101Term: Generalised tonic-clonic seizuresSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-000265-12-HUEisai Limited164
进行中（未招募）
1 期
A Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events when Evolocumab (AMG 145) is used in combination With Statin Therapy In Patients with Clinically Evident Cardiovascular DiseaseMedDRA version: 18.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 18.1Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861DyslipidemiaEUCTR2012-001398-97-FIAmgen Inc27,500